Every pharma brand team knows what it's spending on digital advertising. Almost none of them know what their competitors are running.
Pharma digital advertising, meaning the paid search, banner, email, social, and AI-platform campaigns pharma brands use to reach HCPs and patients, has become the industry's dominant marketing channel. Pharma now accounts for 88% of the broader healthcare industry's total digital ad spend, with the category spending an estimated $19.45 billion on online marketing in 2024 alone, a figure projected to keep climbing through 2026 (eMarketer). But most brand and digital marketing teams are optimizing that spend while flying blind on one critical variable: what everyone else in their therapeutic area is doing with theirs.
That's not really a data problem. It's a visibility problem, and it's exactly where competitive intelligence changes the equation.
What Counts as Pharma Digital Advertising Today
Pharma digital advertising spans more channels than most measurement approaches capture. A complete picture includes:
- Paid search: both branded and unbranded terms
- Banner and display ads: on endemic (healthcare) and non-endemic (general web) sites
- Email: from the manufacturer directly and through third-party health publishers
- Social media: organic and paid placements
- AI-generated responses: how brands and competitors are portrayed in Google AI Overviews and Med AI platforms
Most measurement stacks were built to track the first two or three of these, and AI-generated answers are already a bigger part of the picture than most teams assume. In a recent month, 1 in 10 tracked Google searches by verified HCPs and patients, 4,642 of 46,609 queries, triggered an AI-generated response instead of a traditional results page. Very few measurement approaches are built to see all five channels, and that gap is exactly where the competitive blind spot starts.
Why Pharma Brand Teams Can't See What Competitors Are Doing
Ask a digital marketing or insights lead how their agency reports on competitive activity, and the answer is usually some version of "directionally." That's not really a knock on the agency. It's a structural limitation of how competitive data gets collected in this category today.
The problem with agency self-reporting. Brands largely rely on their own media agencies and data vendors for intelligence on the competitive landscape. Because agencies report on their own campaigns, brand teams have no independent benchmark for how their digital footprint compares to competitors'. They're evaluating their own performance in a vacuum, with click-through and conversion rates that say nothing about whether a competitor is outspending them three times over on the same channel.
The problem with survey-based estimates. Traditional approaches to understanding channel priority lean on physician and patient surveys to infer which sites or platforms matter most. Surveys are useful for capturing sentiment, but they're limited by recall bias. A physician asked months later where they research treatment options online isn't going to accurately reconstruct their actual browsing behavior.
The problem with incomplete channel coverage. Publishers can share NPI-level reach lists, but those don't reveal which sites HCPs visit most when researching a therapy. And almost no measurement approach captures non-endemic sites or third-party email content, and the scale of that blind spot is bigger than most teams expect. In a recent month, 91.3% of the roughly 233,000 banner ad impressions Digital Tracker captured came from non-endemic, non-healthcare sites, meaning 9 out of 10 ad exposures happened somewhere legacy measurement typically isn't looking. Email tells a similar story: 59.8% of pharma-relevant emails HCPs received that month came from third-party publishers, versus 31.9% from the manufacturer directly and 6.4% from a rep. Those are exactly the channels that are only growing in influence as HCPs and patients increasingly research treatments through generative AI tools before they ever land on a branded site.
The result: brand teams can tell you exactly how their own campaign performed. Few can tell you, with any confidence, what a competitor's creative says, which sites its banner ads ran on, or whether its email cadence just changed ahead of a launch.
What Competitive Intelligence Reveals
Competitive intelligence in digital advertising works differently than a modeled spend estimate. It's built on direct observation of what competitors are doing, captured the same way HCPs and patients experience it. That distinction matters because it changes what a brand team can act on. A few categories of insight tend to stand out.
The creative itself. The real ad copy, creative assets, email subject lines, and email content a competitor is running, not just the fact that they're active on a channel. That's direct visibility into how they're positioning against you, not only where they're showing up.
Channel-by-channel activity. Which sites carry a competitor's banner ads, endemic or non-endemic, whether their email strategy leans on manufacturer-owned lists or third-party publishers, and how their paid search mix splits between branded and unbranded terms. This is usually where competitive intelligence diverges most from what an agency can report, since it requires observing a competitor's activity independently rather than modeling it.
How the audience is responding. Real-time web browsing behavior from verified HCPs and patients: which brands they're researching, how much time they spend on each, and which sources are shaping their view of a therapeutic area. That's a very different picture than a self-reported click-through rate that only speaks to a brand's own campaign.
How Passive Observation Changes the Picture
The methodology behind this kind of visibility matters as much as the data itself. Rather than relying on pixel-based tracking, which only sees a brand's own site traffic, or periodic surveys, which rely on recall, a passive, observational approach captures real activity and impressions in real time, directly from verified panelists who are confirmed target HCPs or patients, not modeled samples.
Applied at scale, this is what Digital Tracker does. It passively observes verified HCP and patient behavior across banner ads, paid search, email, social, web browsing, and Med AI platforms, capturing over 410,000 banner ad impressions, 44,000+ paid search impressions, and 27,000+ emails every month, alongside 45,000+ healthcare webpage visits, all tied to verified target audiences rather than estimated ones. That level of channel-level detail is what makes it possible to see how a specific competitor executes in a specific channel, not just that they're active in it.
Putting Competitive Intelligence to Work
What a brand team does with this visibility depends on where it sits in the product lifecycle.
Pre-launch and early launch teams use it to define the competitive landscape before their own campaign goes live: understanding how the audience currently researches treatment options, which sources are already shaping AI-generated narratives about the therapeutic area, and which channels competitors are prioritizing, so the brand isn't building a media plan in a vacuum.
Post-launch brand teams use it to measure share of voice against named competitors on a recurring cadence, link campaign activity back to brand health metrics, and identify whitespace, meaning channels or sites competitors haven't claimed yet, before a competitor gets there first.
Both use cases share the same underlying requirement: intelligence that's tied to verified behavior, refreshed regularly enough to catch a competitor's messaging shift or channel pivot, and specific enough to inform where the next media dollar should go, not just how the last one performed.
Closing the Visibility Gap
Pharma digital advertising has outgrown the measurement tools most brand teams still rely on. Agency self-reporting and survey-based estimates were built for a simpler channel mix, not one that now spans six-plus digital channels plus AI-generated answers. Digital Tracker closes that gap by replacing modeled estimates with direct, verified observation of what competitors are doing, in the channels HCPs and patients actually use.
To see what that kind of visibility looks like for your own competitive set, talk to the Digital Tracker team.
